Chicago Capital LLC Has $17.35 Million Stake in Thermo Fisher Scientific Inc. $TMO

Chicago Capital LLC lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 35,762 shares of the medical research company’s stock after selling 1,774 shares during the period. Chicago Capital LLC’s holdings in Thermo Fisher Scientific were worth $17,345,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of TMO. Norges Bank acquired a new position in shares of Thermo Fisher Scientific during the second quarter valued at $2,264,615,000. Soundwatch Capital LLC bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $807,713,000. Flossbach Von Storch SE lifted its position in Thermo Fisher Scientific by 93.0% during the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock valued at $1,105,698,000 after purchasing an additional 1,314,182 shares during the period. EdgePoint Investment Group Inc. boosted its stake in shares of Thermo Fisher Scientific by 282.5% in the 2nd quarter. EdgePoint Investment Group Inc. now owns 1,323,065 shares of the medical research company’s stock valued at $536,450,000 after purchasing an additional 977,127 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Thermo Fisher Scientific by 58.2% during the second quarter. The Manufacturers Life Insurance Company now owns 2,293,264 shares of the medical research company’s stock worth $929,828,000 after buying an additional 843,267 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Frederick M. Lowery sold 6,913 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $597.68, for a total transaction of $4,131,761.84. Following the completion of the transaction, the executive vice president owned 14,367 shares in the company, valued at approximately $8,586,868.56. This represents a 32.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 17,104 shares of the business’s stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $573.54, for a total value of $9,809,828.16. Following the completion of the sale, the chief executive officer owned 113,762 shares in the company, valued at approximately $65,247,057.48. This trade represents a 13.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 149,271 shares of company stock worth $86,507,282. Company insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on TMO shares. The Goldman Sachs Group assumed coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, December 9th. They issued a “buy” rating and a $685.00 price objective on the stock. TD Cowen increased their price target on Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a research note on Wednesday, October 8th. Barclays increased their target price on Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Finally, Wells Fargo & Company boosted their target price on Thermo Fisher Scientific from $635.00 to $675.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $619.60.

Thermo Fisher Scientific Stock Up 3.2%

NYSE:TMO opened at $611.23 on Tuesday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $611.45. The stock has a 50-day moving average price of $576.92 and a two-hundred day moving average price of $512.10. The stock has a market cap of $229.65 billion, a price-to-earnings ratio of 35.31, a PEG ratio of 3.90 and a beta of 0.91. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating the consensus estimate of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.Thermo Fisher Scientific’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific announced that its Board of Directors has approved a share buyback program on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is currently 9.94%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.